Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Letter to the Editor: Modern Management of Newly Diagnosed Vulvovaginal Melanoma: Is There a Role for Carbon Ion Radiotherapy? A Perspective From the Particle Therapy Co-Operative Group (PTCOG) Gynecological Subcommittee.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review.

Critical reviews in oncology/hematology·2026

Same author

Reconsidering PARP inhibitor-radiotherapy combinations in the stereotactic era.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026

Same author

Hold the line: Local control strategies in oligoprogressive gynecologic cancers during systemic therapy.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Biological effectiveness of high-energy proton transmission beams:<i>in vitro</i>evaluation of cell survival and viability.

Physics in medicine and biology·2026

Same author

Stereotactic body radiotherapy for oligorecurrent granulosa cell tumours.

Gynecologic oncology·2026

Search research articles

Related Experiment Video

Updated: Oct 15, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Hadrontherapy for Thymic Epithelial Tumors: Implementation in Clinical Practice.

Pierre Loap^1,2, Viviana Vitolo², Amelia Barcellini²

¹Department of Radiation Oncology, Institut Curie, Paris, France.

Frontiers in Oncology

|October 28, 2021

Summary

Modern radiation therapy, including hadrontherapy (proton and carbon ion therapy), offers improved safety for thymic epithelial tumors (TETs) by sparing organs at risk. Further clinical research is needed to expand its use.

Keywords:

carbon ion therapy hadrontherapy proton therapy thymic carcinoma thymoma

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Experiment Videos

Last Updated: Oct 15, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Area of Science:

Radiation Oncology
Medical Physics
Thoracic Surgery

Background:

Radiation therapy is a standard treatment for thymic epithelial tumors (TETs).
Older radiation techniques led to significant toxicity in organs at risk (OARs) like the heart and lungs.
Advancements in radiation therapy have improved tissue sparing without compromising tumor coverage.

Purpose of the Study:

To review the current status of hadrontherapy for TET irradiation.
To assess the potential of hadrontherapy for wider clinical implementation.
To highlight the benefits of hadrontherapy in complex cases, such as cardiac involvement.

Main Methods:

Critical review of existing literature on hadrontherapy for TETs.
Analysis of dosimetric advantages and clinical outcomes of proton and carbon ion therapy.
Evaluation of current clinical experience and limitations.

Main Results:

Hadrontherapy, including proton and carbon ion therapy, demonstrates significant dosimetric advantages for TET irradiation.
Modern techniques effectively spare OARs, potentially reducing radiation-induced toxicity.
Clinical data, primarily from small proton therapy studies, indicate promise but highlight limited experience.

Conclusions:

Hadrontherapy is a promising approach for TET irradiation, especially in challenging scenarios.
Further clinical studies are essential to support large-scale implementation of hadrontherapy for TETs.
Continued research will refine treatment protocols and expand the application of advanced radiation techniques.